Royalty Pharma (RPRX) EBITDA Margin (2019 - 2026)
Royalty Pharma (RPRX) reported EBITDA Margin of 89.29% for Q1 2026, down 472.0% on a YoY basis from 24.0% in Q1 2025, and up 43.0% sequentially from 62.44% in Q4 2025.
Royalty Pharma (RPRX) EBITDA Margin (2019 - 2026) Analysis & Trends
Royalty Pharma (RPRX) has 8 years of EBITDA Margin data on file, last reported at 89.29% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 472.0% year-over-year to 89.29%; the trailing twelve-month figure through Mar 2026 stood at 65.08% (down 1886.0% YoY), and the FY2025 full-year result was 65.58%, up 848.0% from the prior year.
- EBITDA Margin improved to 89.29% in Q1 2026, from 62.44% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 130.17% in Q3 2024 to a low of 85.31% in Q4 2022.
- A 5-year average of 52.09% and a median of 60.9% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin tumbled 11196 bps in 2022 and soared 18814 bps in 2023, its largest moves.
- Tracing RPRX's EBITDA Margin over 5 years: stood at 85.31% in 2022, then jumped by 221 bps to 102.82% in 2023, then plunged by 41 bps to 60.9% in 2024, then grew by 3 bps to 62.44% in 2025, then jumped by 43 bps to 89.29% in 2026.
- Business Quant data shows RPRX's EBITDA Margin at 89.29% in Q1 2026, 62.44% in Q4 2025, and 70.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 89.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.29% |
| Dec 31, 2025 | 62.44% |
| Sep 30, 2025 | 70.11% |
| Jun 30, 2025 | 36.26% |
| Mar 31, 2025 | 94.01% |
| Dec 31, 2024 | 60.90% |
| Sep 30, 2024 | 130.17% |
| Jun 30, 2024 | 50.19% |
| Mar 31, 2024 | -12.99% |
| Dec 31, 2023 | 102.82% |
| Sep 30, 2023 | 28.24% |
| Jun 30, 2023 | 46.24% |
| Mar 31, 2023 | 70.03% |
| Dec 31, 2022 | -85.31% |
| Sep 30, 2022 | 33.52% |
| Jun 30, 2022 | 70.49% |
| Mar 31, 2022 | 39.09% |
| Dec 31, 2021 | 26.65% |
| Sep 30, 2021 | 51.74% |
| Jun 30, 2021 | 134.23% |